热门资讯> 正文
Skye Bioscience Starts Screening Patients for Phase 2 Trial of Potential Weight Loss Drug
2024-08-22 19:31
07:31 AM EDT, 08/22/2024 (MT Newswires) -- Skye Bioscience (SKYE) said Thursday that it has started screening patients for a phase 2 clinical trial of nimacimab as a weight loss therapeutic for patients with obesity.
The company said the trial is targeting enrollment of 120 patients, with weight loss as the primary endpoint. Secondary endpoints include safety, tolerability, and neuropsychiatric and cognitive evaluation, among others, Skye Bioscience added.
Interim data from the trial is expected in Q2 2025 and final data in Q4 2025, the company said.
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
